©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 28, 2014; 20(40): 14865-14874
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14865
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14865
Table 1 Inclusion and exclusion criteria
| Inclusion criteria |
| Age ≥ 18 yr and ≤ 65 yr |
| Typical symptoms: regurgitation and heartburn |
| Atypical symptoms: belching, chest pain, pharyngeal burning, foreign body sensations, chronic unexplained pharyngitis, hoarseness, bronchitis, and asthma |
| Proton pump inhibitor therapy-positive |
| Written informed consent |
| Exclusion criteria |
| Nasopharynx or upper esophagus obstruction |
| Esophageal varices and severe esophageal mucosal erosion |
| Severe esophageal motility disorder (e.g., achalaisa, scleroderma, diabetes mellitus, autonomic or peripheral neuropathy, and myopathy) |
| In vivo congenital gastrointestinal malformation, gastrointestinal obstruction, perforation, stricture, or fistula |
| A recent history of stomach surgery or gastrointestinal bleeding (within the past 6 mo) |
| A history of bleeding tendency and taking anticoagulant drugs in the long term |
| Any implanted electrical device, such as cardiac pacemakers |
| Allergy to the polymer materials |
| Various acute enteritis, severe ischemic disease, or radioactive colitis |
| Pregnancy/lactation |
| Unstable cardiopathy, psychotic diseases arrhythmia cordis, or being uncooperative |
- Citation: Yang XJ, Gan T, Wang L, Liao Z, Tao XH, Shen W, Zhao XY. Wireless esophageal pH capsule for patients with gastroesophageal reflux disease: A multicenter clinical study. World J Gastroenterol 2014; 20(40): 14865-14874
- URL: https://www.wjgnet.com/1007-9327/full/v20/i40/14865.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i40.14865